Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,805.00
(
0.41%
)
News Focus
News Focus
Post# of 257266
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: drbio45 post# 1794

Tuesday, 04/13/2004 11:18:34 PM

Tuesday, April 13, 2004 11:18:34 PM

Post# of 257266
More on CJC:

>> I sold the last of my cjc. The technology is great, but I think there will be some weakness until the next data set comes out in July <<

Smart move, IMHO. I think the ConjuChem situation is the mirror image of FMTI: with FMTI, investors were too negative, but with CJC they appear to be too positive.

CJC is spinning the interim results as an A or A- grade, but my assessment is B-/C+. The company concedes that nausea can be a limiting factor on dosing, and this is troubling from a competitive standpoint.

The maximum dose has been cut 20% (from 10mcg/kg to 8mcg/kg) in the next study, and it’s reasonable to assume that a lower dose will produce a somewhat shorter duration of action. If CJC’s drug has to be given more often than originally expected, how will it compete with Exenatide LAR –or even with the short-acting Exenatide?

This looks like a case where the hype may have overstepped the reality to some degree.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now